(Corrects source in story body to Immunai from AstraZeneca) Oct 16 (Reuters) – IMMUNAI: * IMMUNAI: AGREEMENT TO ADVANCE AN INFLAMMATORY BOWEL DISEASE TARGET WITH ASTRAZENECA * IMMUNAI: UNDER TERMS IMMUNAI WILL RECEIVE AN UPFRONT PAYMENT AND IS ELIGIBLE TO RECEIVE UP TO $85M IN TOTAL CONSIDERATION Source text: Further company coverage:
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)